AFAP1L2 and hepatocellular carcinoma: ART mitigates sorafenib resistance in hepatocellular carcinoma (HCC) patients by exacerbating AFAP1L2-SRC-FUNDC1 axis-dependent mitochondrial autophagy (Ma Z. et al., 2024) (Figure 2).